News
Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...
The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.
The companies' new effort would bypass traditional middlemen to cut the drug's monthly cost from a list price of around $606 ...
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Pfizer here.
A look at the shareholders of Pfizer Inc. (NYSE:PFE) can tell us which group is most powerful. The group holding the most ...
Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.
Explore more
Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
The move is expected to cause a “near-term stock out of Bicillin L-A,” Pfizer said in its statement, with the drugmaker now allocating “limited quantities of inventory to customers during this period ...
After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...
The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...
Pfizer acquired Seagen in 2023 for $43 billion, and shut down construction on a $350 million manufacturing facility the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results